ABBVIE INC (ABBV) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s valuation.

Top 12 Stock Recommendations. In this article, we will take a look at where AbbVie Inc. (NYSE:ABBV) stands against other top stock recommendations by ChatGPT. After a two-year surge of 53% ...

In the latest market close, AbbVie (ABBV) reached $170.16, with a -1.64% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 2.36% for the day.

Rob Stothard / Bloomberg via Getty Images AbbVie's first-quarter sales and adjusted earnings per share topped estimates. The drugmaker lifted its full-year adjusted EPS forecast by 10 cents.

On this episode of Stock Movers: - AbbVie (ABBV) is lower this morning alongside pharma stocks as President plans to order a cut in US prescription drug costs by mandating that Americans pay no ...

Over the last five years, AbbVie's stock has experienced a negative price reaction on the day following its earnings announcement in 57% of cases. The median negative return during these instances ...

Fintel reports that on May 14, 2025, Citigroup downgraded their outlook for AbbVie (NYSE:ABBV) from Buy to Neutral. Analyst ...

ABBV) stock an investor darling on Friday. The pharmaceutical company's performance pushed its stock to a more than 3% gain on the day, well higher than the 0.6% bump of the bellwether S&P 500 ...

With rates going higher, you have to wonder if AbbVie’s worth the risk, even as it’s among the safest, if not the safest stock in the group, because of these amazing franchises. I think it ...